ANTXR1 and gastric neoplasm: Recently, Sotoudeh et al. reported that ANTXR1 was overexpressed in GC and a promising molecular target for both clinical and preclinical assessment for immunotherapy of stomach cancer (Sotoudeh et al., 2019).